This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lenzo, J. C.
Right arrow Articles by Lawson, C. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lenzo, J. C.
Right arrow Articles by Lawson, C. M.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, May 2001, p. 1444-1449, Vol. 45, No. 5
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.5.1444-1449.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

Ganciclovir and Cidofovir Treatment of Cytomegalovirus-Induced Myocarditis in Mice

Jason C. Lenzo,1,2 Geoffrey R. Shellam,2 and Cassandra M. Lawson1,*

Division of Veterinary and Biomedical Sciences, Murdoch University,1 and Department of Microbiology, The University of Western Australia,2 Perth, Western Australia

Received 6 November 2000/Returned for modification 29 January 2001/Accepted 15 February 2001

The cardiovascular disease myocarditis is characterized by inflammation and necrosis of cardiac muscle. This disease has been associated with various viral etiologies, including cytomegalovirus (CMV). Murine CMV (MCMV) infection of adult BALB/c mice produces a disease with acute and chronic phases similar to that found in humans. In our murine model, we have investigated the therapeutic efficacy of antiviral drug administration on myocarditis. Two drugs commonly used for CMV treatment, ganciclovir and cidofovir, were subjected to trials, with both drugs showing potent antiviral activity against MCMV both in vitro and in vivo. The acute phase of myocarditis was significantly reduced when antiviral therapy commenced 24 h postinfection. Such treatment also reduced the severity of the chronic phase of myocarditis. In contrast, antiviral treatment commencing after the acute phase had no effect on chronic myocarditis. Reinfection of mice with MCMV caused exacerbation of myocardial inflammation. Such an increase in severity of myocarditis could be prevented with either ganciclovir or cidofovir treatment, but the preexisting inflammation and necrosis of the myocardium persisted. These data highlight possible therapeutic uses of antiviral drugs in viral myocarditis as well as further elucidating the pathogenic nature of the disease.


* Corresponding author. Mailing address: Division of Veterinary and Biomedical Sciences, Murdoch University, South St., Perth 6150, Australia. Phone: 618 9360 2267. Fax: 618 9310 4144. E-mail: cassiel{at}numbat.murdoch.edu.au.


Antimicrobial Agents and Chemotherapy, May 2001, p. 1444-1449, Vol. 45, No. 5
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.5.1444-1449.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.



This article has been cited by other articles:

  • Brunetti, L., DeSantis, E. R. H. (2008). Treatment of viral myocarditis caused by coxsackievirus B. Am J Health Syst Pharm 65: 132-137 [Abstract] [Full Text]  
  • De Clercq, E. (2003). Clinical Potential of the Acyclic Nucleoside Phosphonates Cidofovir, Adefovir, and Tenofovir in Treatment of DNA Virus and Retrovirus Infections. Clin. Microbiol. Rev. 16: 569-596 [Abstract] [Full Text]